Neuromyelitis Optica Spectrum Disorder
📧 Sign up to get email alerts when something new happens for Neuromyelitis Optica Spectrum Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-12Clinical Trial Update: Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
This clinical trial is a multicenter retrospective observational study evaluating the clinical impact of AI-assisted MRI care in multiple sc…
-
CLINICAL_TRIALS research · 2025-12-09Clinical Trial Update: Autonomic Dysfunction in Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis : A Comparative Study
This clinical trial update describes a study comparing autonomic dysfunction in neuromyelitis optica spectrum disorder and multiple sclerosi…
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders [Phase 2]
A Phase 2 clinical trial of BAT4406F injection for Neuromyelitis Optica Spectrum Disorder is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder [Phase 2]
Amgen is conducting a Phase 2 pediatric trial of Inebilizumab for Neuromyelitis Optica Spectrum Disorder. The study is currently recruiting.
-
FDA approval · 2025-11-24FDA Approved: BKEMV — Supplemental Application (Amgen Inc)
The FDA approved a supplemental application for BKEMV (eculizumab-aeeB) from Amgen, a biosimilar to eculizumab.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) [Phase 4]
This update describes a Phase 4, long-term, open-label safety study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) that i…
-
CLINICAL_TRIALS research · 2025-11-12Clinical Trial Update: Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD [Phase 2, Phase 3]
A pediatric Phase 2/3 study is evaluating Ravulizumab IV for Neuromyelitis Optica Spectrum Disorder. The trial is currently recruiting.
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) [Phase 3]
Phase 3 clinical trial of MIL62 for neuromyelitis optica spectrum disorder is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder [Phase 2]
Clinical trial update indicating a Phase 2 study of eculizumab for acute attacks in neuromyelitis optica spectrum disorder is currently recr…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: Efficacy and Safety of Monoclonal Antibody in Acute Phase of Neuromyelitis Optica Spectrum Disorder
A clinical trial update reports on the efficacy and safety of a monoclonal antibody in the acute phase of Neuromyelitis Optica Spectrum Diso…
-
CLINICAL_TRIALS withdrawal · 2025-09-10Clinical Trial Update: Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder [Phase 2]
The phase 2 trial evaluating eculizumab for acute attacks of neuromyelitis optica spectrum disorder has been withdrawn.
-
CLINICAL_TRIALS research · 2025-09-08Clinical Trial Update: Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
Clinical trial update on monoclonal antibody therapies for AQP4-positive neuromyelitis optica spectrum disorder, with recruitment ongoing at…
-
CLINICAL_TRIALS research · 2025-09-08Clinical Trial Update: Inectolizumab With Steroid Optimization in Newly Treated NMOSD [NA]
Clinical trial update indicates Inectolizumab with steroid optimization is being studied for newly treated neuromyelitis optica spectrum dis…
-
FDA approval · 2025-09-02FDA Approved: EPYSQLI — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approves a supplemental application for EPYSQLI (eculizumab-aagh) from Teva Pharmaceuticals USA, Inc.
-
CLINICAL_TRIALS research · 2025-08-17Clinical Trial Update: Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD) [EARLY_Phase 1]
An early-phase (EARLY_PHASE1) clinical study of B001 Injection in Neuromyelitis optica spectrum disorder is currently recruiting.
-
CLINICAL_TRIALS research · 2025-08-05Clinical Trial Update: Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder
A study is evaluating the clinical and radiological effects of ravulizumab in people with neuromyelitis optica spectrum disorder. Recruitmen…
-
CLINICAL_TRIALS research · 2025-07-28Clinical Trial Update: Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases [NA]
A clinical trial update indicates a study evaluating transcranial alternating current stimulation for cognitive impairment in idiopathic inf…
-
CLINICAL_TRIALS withdrawal · 2025-07-16Clinical Trial Update: A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders [Phase 2]
A Phase IIb trial of nabiximols for spasticity in neuromyelitis optica spectrum disorders has been withdrawn.
-
CLINICAL_TRIALS research · 2025-07-01Clinical Trial Update: Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) Levels in Patients With Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD)
A clinical study is evaluating the effects of ravulizumab, a complement C5 inhibitor, on serum biomarkers sNfL and sGFAP in patients with Aq…
-
CLINICAL_TRIALS trial_result · 2025-06-23Clinical Trial Update: Efficacy and Safety of Conventional Immunosuppressant Therapies in Elderly Patients With Neuromyelitis Optica Spectrum Disorder
This completed clinical trial assessed the efficacy and safety of conventional immunosuppressant therapies in elderly patients with neuromye…
-
CLINICAL_TRIALS research · 2025-06-19Clinical Trial Update: Effects of Transcranial Electrical Stimulation on Cognitive Impairment in CNS Inflammatory Demyelinating Diseases [NA]
A clinical trial is evaluating whether transcranial electrical stimulation can improve cognitive impairment in CNS inflammatory demyelinatin…
-
CLINICAL_TRIALS research · 2025-06-15Clinical Trial Update: Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating BAFF-R CAR-T cell therapy for refractory neuroimmune diseases is currently recruiting.
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases [Phase 1]
This Phase 1 study evaluates LCAR-AIO CAR-T cells for relapsed/refractory neurological autoimmune diseases, recruiting at a major Chinese me…
-
CLINICAL_TRIALS trial_result · 2025-05-30Clinical Trial Update: Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder [Phase 1, Phase 2]
A clinical trial registry update describes the phase 1/2 evaluation of BAFFR CAR T cells for relapsed or refractory Neuromyelitis Optica Spe…
-
CLINICAL_TRIALS research · 2025-05-20Clinical Trial Update: Biorepository and Registry for Plasma Exchange Patients
A clinical trial update announcing a biorepository and registry for patients undergoing plasma exchange, with recruiting status and listed i…